Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Dickson

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Cancer Science|February 7, 2016
Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivityGary K Schwartz, Mark A Dickson, Patricia M LoRusso, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare PartnersKonstantinos Linos, Josephine K Dermawan, Tejus Bale, et al.
Sarcoma|November 27, 2018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing TherapyEdwin Choy, Karla Ballman, James Chen, et al.
Nature Communications|September 1, 2017
ATRX is a regulator of therapy induced senescence in human cellsMarta Kovatcheva, Will Liao, Mary E Klein, et al.
Sarcoma|September 20, 2019
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"Edwin Choy, Karla Ballman, James Chen, et al.
The American Journal of Surgical Pathology|February 5, 2015
Dichotomy of Genetic Abnormalities in PEComas With Therapeutic ImplicationsNarasimhan P Agaram, Yun-Shao Sung, Lei Zhang, et al.
Cancers|October 14, 2023
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue SarcomasSteven Attia, Victor Villalobos, Nadia Hindi, et al.
Investigational New Drugs|December 6, 2014
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumorsMark A Dickson, Michael S Gordon, Gerald Edelman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trialJason J Luke, David R D'Adamo, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2019
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi SarcomaErin G Reid, Adrienne Suazo, Shelly Y Lensing, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Cancer Science|February 7, 2016
Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivityGary K Schwartz, Mark A Dickson, Patricia M LoRusso, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare PartnersKonstantinos Linos, Josephine K Dermawan, Tejus Bale, et al.
Sarcoma|November 27, 2018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing TherapyEdwin Choy, Karla Ballman, James Chen, et al.
Nature Communications|September 1, 2017
ATRX is a regulator of therapy induced senescence in human cellsMarta Kovatcheva, Will Liao, Mary E Klein, et al.
Sarcoma|September 20, 2019
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"Edwin Choy, Karla Ballman, James Chen, et al.
The American Journal of Surgical Pathology|February 5, 2015
Dichotomy of Genetic Abnormalities in PEComas With Therapeutic ImplicationsNarasimhan P Agaram, Yun-Shao Sung, Lei Zhang, et al.
Cancers|October 14, 2023
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue SarcomasSteven Attia, Victor Villalobos, Nadia Hindi, et al.
Investigational New Drugs|December 6, 2014
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumorsMark A Dickson, Michael S Gordon, Gerald Edelman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trialJason J Luke, David R D'Adamo, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2019
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi SarcomaErin G Reid, Adrienne Suazo, Shelly Y Lensing, et al.
Pageof 8